Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
Invesco Health Care A GGHCX
- NAV / 1-Day Return 38.29 / +0.26 %
- Total Assets 1.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.060%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 59%
USD | NAV as of May 01, 2024 | 1-Day Return as of May 01, 2024, 10:14 PM GMT+0
Morningstar’s Analysis GGHCX
Will GGHCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 9.09 | 124.8 Mil | Healthcare |
Boston Scientific Corp | 5.32 | 73.1 Mil | Healthcare |
UnitedHealth Group Inc | 5.24 | 71.9 Mil | Healthcare |
McKesson Corp | 4.18 | 57.4 Mil | Healthcare |
Merck & Co Inc | 3.66 | 50.3 Mil | Healthcare |
Stryker Corp | 3.55 | 48.8 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 3.53 | 48.4 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.47 | 47.6 Mil | Healthcare |
Intuitive Surgical Inc | 3.26 | 44.7 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.21 | 44.1 Mil | Healthcare |